Enliven Therapeutics (ELVN) director gets 59,372 stock options grant

Rhea-AI Filing Summary

Enliven Therapeutics director Garland J. Scott reported a new stock option grant on a Form 4. On January 7, 2026, he was awarded a stock option to buy 59,372 shares of Enliven Therapeutics, Inc. common stock at an exercise price of $15.47 per share, expiring on January 7, 2036. The filing states that one‑thirty‑sixth of the shares subject to the option will vest on February 7, 2026 and then monthly thereafter, as long as he continues serving as an outside director on each vesting date. The option is reported as directly owned and was granted at a price of $0 for the derivative itself.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Garland J. Scott

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	59,372	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 59,372 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Garland J. Scott

(Last) (First) (Middle)

C/O ENLIVEN THERAPEUTICS, INC.

6200 LOOKOUT ROAD

(Street)

BOULDER CO 80301

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Enliven Therapeutics, Inc. [ ELVN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/07/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$15.47	01/07/2026		A		59,372		(1)	01/07/2036	Common Stock	59,372	$0	59,372	D

Explanation of Responses:

1. 1/36th of the shares subject to the option will vest on February 7, 2026 and each month thereafter, subject to the Reporting Person continuing as an outside director through each such date.

	/s/ Ben Hohl, by power of attorney	01/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Enliven Therapeutics (ELVN) report on this Form 4?

The Form 4 reports that director Garland J. Scott received a stock option (right to buy) on January 7, 2026 covering 59,372 shares of Enliven Therapeutics, Inc. common stock.

What is the exercise price and expiration date of Garland J. Scott’s Enliven (ELVN) stock option?

The stock option has an exercise price of $15.47 per share and an expiration date of January 7, 2036, with 59,372 underlying shares of common stock.

How does the Enliven Therapeutics (ELVN) stock option granted to Garland J. Scott vest?

The footnote explains that 1/36th of the shares subject to the option will vest on February 7, 2026 and each month thereafter, as long as he continues as an outside director on each vesting date.

How many derivative securities does Garland J. Scott hold in Enliven Therapeutics after this transaction?

After the reported grant, Garland J. Scott beneficially owns 59,372 derivative securities in the form of this stock option, reported as direct (D) ownership.

What role does the reporting person hold at Enliven Therapeutics (ELVN)?

The reporting person, Garland J. Scott, is identified as a Director of Enliven Therapeutics, Inc. and is described as an outside director for vesting purposes.

Did Garland J. Scott pay for the Enliven Therapeutics option itself?

The Form 4 shows a price of $0 for the derivative security, meaning the option grant itself did not have a purchase price, while the exercise price for the underlying shares is $15.47 per share.